Merck Is Mercury, Schering Is Saturn; Is J&J The Death Star?
This article was originally published in The Pink Sheet Daily
Executive Summary
SEC documents reveal Schering-Plough will owe Merck $1.5 billion if their proposed deal collapses. The earthly break-up fee could spur J&J to make a counter-offer.
You may also be interested in...
Merck/Schering: The Next Wave Of Consolidation
$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.
Will Johnson & Johnson Undercut Merck’s Bid to Buy Schering-Plough?
A 1998 change-of-control provision tied to Remicade complicates Merck’s attempted mega-merger.
Jardiance Improves Double-Digit Growth Potential With US Approval In CKD
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.